Promising First Results With DNA Editing to Lower LDL : vima

The first-in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial hypercholesterolemia.

Related Keywords

Philadelphia , Pennsylvania , United States , American , Andrew Bellinger , Karol Watson , Amgen , Novartis , American Heart Association , Verve Therapeutics , American Heart , Lipids , Ipid Management , Cv , Ardiovascular , Pcsk9 , Roprotein Convertase Subtilisin Kexin Type 9 , Genomics , Genomic Medicine , Edicine Genomic , Liver , Aminotransferase , Dust , Liver Enzymes , Liver Studies , Olt , Familial Hypercholesterolemia , Hypercholesterolemia , Gene Editing , Genetic Editing , Low Ldl Cholesterol , Ypobetalipoproteinemia , Ow Low Density Lipoprotein Cholesterol , Biologic Therapy , Gene Ther ,